These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34755315)

  • 1. Healthcare disparities in heart failure patients (with and without type 2 diabetes) and use of sodium glucose co-transport inhibitors (SGLT2-i).
    Madan S; Farooq M; Diab K; Melainis AA; DiPalo KE; Crandall JP; Rodriguez CJ; Jorde UP
    Endocrine; 2022 Feb; 75(2):654-658. PubMed ID: 34755315
    [No Abstract]   [Full Text] [Related]  

  • 2. Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.
    Cheng JWM; Colucci V; Kalus JS; Spinler SA
    Ann Pharmacother; 2021 Feb; 55(2):252-260. PubMed ID: 32536199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors.
    Vaduganathan M; Januzzi JL
    Am J Cardiol; 2019 Dec; 124 Suppl 1():S20-S27. PubMed ID: 31741436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
    Lan NSR; Fegan PG; Yeap BB; Dwivedi G
    ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose co-transporter 2 inhibitors: 'a tale of two sisters', diabetes and heart failure.
    Farmakis D; Butler J; Filippatos G
    Eur J Heart Fail; 2020 Jul; 22(7):1259-1262. PubMed ID: 32533724
    [No Abstract]   [Full Text] [Related]  

  • 6. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
    Lytvyn Y; Bjornstad P; Udell JA; Lovshin JA; Cherney DZI
    Circulation; 2017 Oct; 136(17):1643-1658. PubMed ID: 29061576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial.
    Mordi NA; Mordi IR; Singh JS; Baig F; Choy AM; McCrimmon RJ; Struthers AD; Lang CC
    BMJ Open; 2017 Oct; 7(10):e018097. PubMed ID: 29042392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
    Packer M
    Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure.
    Seferović PM; Fragasso G; Petrie M; Mullens W; Ferrari R; Thum T; Bauersachs J; Anker SD; Ray R; Çavuşoğlu Y; Polovina M; Metra M; Ambrosio G; Prasad K; Seferović J; Jhund PS; Dattilo G; Čelutkiene J; Piepoli M; Moura B; Chioncel O; Ben Gal T; Heymans S; Jaarsma T; Hill L; Lopatin Y; Lyon AR; Ponikowski P; Lainščak M; Jankowska E; Mueller C; Cosentino F; Lund LH; Filippatos GS; Ruschitzka F; Coats AJS; Rosano GMC
    Eur J Heart Fail; 2020 Nov; 22(11):1984-1986. PubMed ID: 33068051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
    Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH
    J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
    Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R
    Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism.
    Imran H; Nester W; Elgendy IY; Saad M
    Ann Med; 2020 Aug; 52(5):178-190. PubMed ID: 32393068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with sodium-glucose cotransporter-2 inhibitors in heart failure patients: The potential benefits of monitoring FGF-23 levels?
    Gruson D; Pouleur AC; Hermans MP; Ahn SA; Rousseau MF
    Ann Endocrinol (Paris); 2022 Feb; 83(1):78-80. PubMed ID: 34728212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
    Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology.
    Seferović PM; Fragasso G; Petrie M; Mullens W; Ferrari R; Thum T; Bauersachs J; Anker SD; Ray R; Çavuşoğlu Y; Polovina M; Metra M; Ambrosio G; Prasad K; Seferović J; Jhund PS; Dattilo G; Čelutkiene J; Piepoli M; Moura B; Chioncel O; Ben Gal T; Heymans S; de Boer RA; Jaarsma T; Hill L; Lopatin Y; Lyon AR; Ponikowski P; Lainščak M; Jankowska E; Mueller C; Cosentino F; Lund L; Filippatos GS; Ruschitzka F; Coats AJS; Rosano GMC
    Eur J Heart Fail; 2020 Sep; 22(9):1495-1503. PubMed ID: 32618086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.
    Sano M
    J Cardiol; 2018 May; 71(5):471-476. PubMed ID: 29415819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D; Javor E; Lucijanić T; Skelin M
    Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future.
    Nana M; Morgan H; Bondugulapati LNR
    Heart Fail Rev; 2021 Jul; 26(4):953-960. PubMed ID: 32020487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Seidu S; Kunutsor SK; Topsever P; Khunti K
    Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00303. PubMed ID: 34636161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 Inhibitors and Their Antiarrhythmic Properties.
    Kolesnik E; Scherr D; Rohrer U; Benedikt M; Manninger M; Sourij H; von Lewinski D
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.